dual NEP/ECE inhibitor (Abbott)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual NEP/ECE inhibitor (Abbott)
Drug Alias Namedual neutral endopeptidase/endothelin converting enzyme inhibitor (Abbott)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin-converting enzymes inhibitorsNeprilysin inhibitors
TargetsNeprilysinEndothelin-converting enzymes
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott GmbH
Active IndicationsN/A
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A